Solara Active Pharma Sciences Limited (NSE:SOLARA) disclosed the transcript of its Q1 FY27 earnings conference call held on 23 July 2026, filed with the National Stock Exchange and BSE on 29 July 2026 under Regulation 30 of the SEBI Listing Regulations. The company reported consolidated revenue of Rs 384 crores for the April-June 2026 quarter, representing a 20% increase year-on-year, with net profit rising to Rs 16.3 crores, up 55% compared to the same period in the prior fiscal year.
Key Highlights
- Q1 FY27 consolidated revenue reached Rs 384 crores, up 20% year-on-year, marking what management described as strong execution despite operational headwinds.
- Net profit for the quarter stood at Rs 16.3 crores, representing 55% growth year-on-year, the highest PAT achieved in the preceding 18 quarters according to the earnings call.
- EBITDA for Q1 FY27 was Rs 63.5 crores, up 10% year-on-year, with an EBITDA margin of 17%, reflecting an 80 basis point sequential improvement from Q4 FY26.
- The base business, excluding the Ibuprofen segment, delivered revenue of Rs 307 crores, up 24% year-on-year, with gross margin of Rs 158 crores up 10% year-on-year.
- Net debt as of 30 June 2026 stood at approximately Rs 479 crores, down Rs 135 crores from the prior quarter, representing a 22% reduction driven by rights issue proceeds and operational cash generation.
- The Ibuprofen business reported negative EBITDA margin of 12% during Q1 FY27, though management noted marginal sequential improvement from the prior quarter.
- Management reiterated focus on working capital optimization, capacity debottlenecking, and business expansion as operational priorities for the next 12 to 18 months.
About the Company
Solara Active Pharma Sciences Limited is a pharmaceutical company engaged in the manufacture and supply of active pharmaceutical ingredients (APIs) and specialty chemicals for regulated markets across North America, Europe, and other geographies. The company operates manufacturing facilities in India, including operations in Tamil Nadu where its corporate office is located in the TICEL Bio Park, Chennai. The company is listed on the National Stock Exchange (NSE:SOLARA) with scrip code 541540 and on the BSE with scrip code 890202. Solara's portfolio comprises base pharmaceutical ingredients sold to multinational and specialty pharmaceutical companies, alongside a commodity Ibuprofen business that has faced pricing pressures in recent periods. The company completed a rights issue in May 2026 to strengthen its balance sheet, with final call proceeds of approximately Rs 100 crores realized during Q1 FY27.
Announcement in Detail
The earnings conference call held on 23 July 2026 featured remarks from Sandeep Rao, Managing Director and Chief Executive Officer, Sarat Kumar, Chief Financial Officer, and Abhishek Singhal, Head of Investor Relations. During the call, management highlighted that Q1 FY27 represented "another quarter of stellar execution" with consolidated revenue of Rs 384 crores and EBITDA of Rs 63.5 crores. Management attributed performance to disciplined execution and continued focus on profitable growth across the base business portfolio.
The base business segment demonstrated particular strength, with revenues reaching Rs 307 crores, representing 24% year-on-year growth despite input cost pressures stemming from geopolitical developments in West Asia. Management disclosed that gross margin in the base business was Rs 158 crores, up 10% year-on-year, though the company acknowledged facing sustained cost pressures from elevated raw material prices. The broader EBITDA figure of Rs 63.5 crores represented the highest quarterly EBITDA in the preceding 18 quarters, a metric management emphasized to underscore operational resilience.
On debt management, the company reported net debt reduction of approximately Rs 135 crores during Q1 FY27, comprising Rs 100 crores from the final call instalment of the rights issue completed in May 2026 and Rs 35 crores generated from operational cash flows. Net debt as of 30 June 2026 stood at Rs 479 crores, translating to a net debt-to-EBITDA multiple of 1.9x on an annualized basis using Q1 EBITDA. Management indicated a line of sight to reduce net debt to approximately Rs 440 crores by 31 March 2027 through scheduled debt repayments, which would lower the net debt-to-EBITDA ratio to approximately 1.7x based on the Q1 annualized run rate.
Impact on Investors
Investors will note that the company's consolidated profit figures represent the highest PAT achieved in 18 quarters, a metric management highlighted to demonstrate business resilience amid external headwinds. The 55% year-on-year growth in net profit occurred despite acknowledged raw material cost inflation and supply chain disruptions linked to geopolitical events, suggesting that operational discipline and product mix contributed materially to profitability expansion. The disclosed reduction in net debt by Rs 135 crores during a single quarter signals acceleration in balance sheet repair, particularly given the timing of rights issue realization. Shareholders will observe that the debt-to-EBITDA multiple improvement trajectory outlined by management, if realized, would bring leverage closer to normalized levels by fiscal year-end 2027.
The disclosed EBITDA margin improvement of 80 basis points sequentially, combined with a 10% year-on-year increase in absolute EBITDA despite cost headwinds, indicates margin expansion mechanics at work beyond simple volume growth. However, investors should note that the Ibuprofen segment continues to report negative EBITDA margins of 12%, representing a material drag on consolidated profitability. Management's indication that a strategic review of the Ibuprofen business is expected in H1 FY27, with outcomes potentially disclosed by the September 2026 quarter, represents a key event for shareholders to monitor, as resolution of this segment's ongoing losses could materially alter the profitability trajectory.
Sector / Market Context
The global active pharmaceutical ingredients sector experienced significant cost volatility during the first quarter of FY27 due to supply chain disruptions and elevated input costs. Management explicitly referenced West Asia geopolitical developments as a driver of raw material price inflation and logistics challenges affecting global pharmaceutical manufacturers. Against this backdrop, the company's ability to deliver a 20% year-on-year revenue increase and a 55% increase in net profit demonstrates relative operational stability compared to peers facing similar input cost headwinds. The pharmaceutical APIs sector typically operates under margin compression cycles during commodity raw material inflation phases, making the company's reported EBITDA margin of 17% in Q1 a notable data point for relative performance assessment. The Indian pharmaceutical sector has long served as a key supplier of APIs to regulated markets in North America and Europe, positioning companies like Solara in the supply chain resilience conversation as multinational pharmaceutical companies seek stable, diverse sourcing options outside primary geopolitical risk zones.